The effect of furosemide in the prevention of contrast-induced nephropathy in STEMI (ST) Elevation Myocardial Infarction patients undergoing Percutaneous Coronary Intervention (PCI) referred to Golestan Hospital between 2023-2024

The effect of furosemide in the prevention of contrast-induced nephropathy in STEMI patients undergoing Percutaneous Coronary Intervention (PCI)

Clinical trial with control group, with parallel groups, double-blind, randomized, phase 3 on 234 patients (intervention group 117 patients and control group 117 patients), by Software Allocation R software was used for randomization.

This is a clinical trial study that was conducted between 2023-2024 Golestan Hospital, Ahvaz. The study was conducted in a double-blind manner and the patient and the nurse are not aware of the type of medicine. The patients whose disease has been confirmed as STEMI and who are candidates for angiography and angioplasty are divided into two groups. One group receives Furosemide and serum and the other group receives serum. After 24 and 72 hours, their creatinine, blood urea and GFR are measured.

Inclusion criteria: Patients whose disease has been confirmed as STEMI and who are candidates for angiography and angioplasty and who consent to participate in the study and also have complete clinical information, are included in the study. Exclusion criteria: patients whose clinical information is not complete, patients with heart failure And dialysis patients who do not have urinary excretion are excluded from the study.

Intervention group: single dose of furosemide at the rate of 0.5 mg/kg plus standard hydration with normal saline at the rate of 1 mg/kg/h. Control group: standard hydration with normal saline at the rate of 1 mg/kg/h

contrast-induced nephropathy hypertension, diabetes, creatinine, bun GFR

Randomization method and explanations of each method: Based on the method of random permutations, people are divided into two groups completely randomly. Randomization Unit: Individual Randomization tool: Random Allocation Software for randomization, sealed envelope random sequence was built: allocating even numbers to group A and odd numbers to group B allocation concealment: Sealed envelopes that are assigned to each participant upon entering, based on which they will be placed in one of the two groups.

Patients are divided into two groups receiving furosemide and receiving normal saline (placebo) at the rate of 0.5 mg/kg with a ratio of 1:1. This study is conducted in a double-blind manner, so that the patient, the researcher and the outcome assessors will not have any information about which group the people are in and which medicine they will receive. In this way, the drug and placebo will be completely similar in terms of shape, color, smell, etc. The drugs are in sealed packages that are blinded to the researcher, the patient, and the outcome assessors, and it is not clear which patient receives which drug.

Only the results related to the outcome and output of the intervention can be published. It is provided to the researchers to conduct further research.

The data will be available after the publication of the article.

Researchers working in academic and scientific institutions

In meta-analysis studies and conducting similar studies

Refer to the Research and Technology Vice-Chancellor of Jundishapur University of Medical Sciences, Ahvaz. While submitting the proposal and obtaining the code of ethics from the ethics committee of this university, access to this data should be provided for the researchers.

Researchers can access the data through correspondence with the research and technology unit of the university and since obtaining the code of ethics from the research ethics committee of Jundishapur University of Medical Sciences, Ahvaz.